S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Vir Biotechnology (VIR) Competitors

$7.95
-0.01 (-0.13%)
(As of 04/19/2024 ET)

VIR vs. SRRK, TARS, ADAP, KYTX, AUTL, BCRX, RLAY, FDMT, IMTX, and RGNX

Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Scholar Rock (SRRK), Tarsus Pharmaceuticals (TARS), Adaptimmune Therapeutics (ADAP), Kyverna Therapeutics (KYTX), Autolus Therapeutics (AUTL), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), 4D Molecular Therapeutics (FDMT), Immatics (IMTX), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.

Vir Biotechnology vs.

Vir Biotechnology (NASDAQ:VIR) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

In the previous week, Vir Biotechnology had 3 more articles in the media than Scholar Rock. MarketBeat recorded 4 mentions for Vir Biotechnology and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.59 beat Vir Biotechnology's score of 0.25 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scholar Rock
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vir Biotechnology presently has a consensus target price of $34.38, indicating a potential upside of 332.39%. Scholar Rock has a consensus target price of $25.17, indicating a potential upside of 81.71%. Given Vir Biotechnology's higher possible upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Vir Biotechnology has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -713.69%. Vir Biotechnology's return on equity of -34.92% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Vir Biotechnology-713.69% -34.92% -27.73%
Scholar Rock N/A -80.48%-57.10%

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 18.1% of Vir Biotechnology shares are owned by insiders. Comparatively, 26.2% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Scholar Rock has lower revenue, but higher earnings than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$86.18M12.41-$615.06M-$4.59-1.73
Scholar Rock$33.19M32.49-$165.79M-$1.99-6.96

Scholar Rock received 109 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 62.93% of users gave Scholar Rock an outperform vote while only 47.44% of users gave Vir Biotechnology an outperform vote.

CompanyUnderperformOutperform
Vir BiotechnologyOutperform Votes
37
47.44%
Underperform Votes
41
52.56%
Scholar RockOutperform Votes
146
62.93%
Underperform Votes
86
37.07%

Summary

Scholar Rock beats Vir Biotechnology on 13 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIR vs. The Competition

MetricVir BiotechnologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.07B$2.61B$4.87B$7.32B
Dividend YieldN/A2.30%2.92%3.97%
P/E Ratio-1.7320.96183.8816.91
Price / Sales12.41303.162,462.9981.89
Price / CashN/A139.9547.3834.38
Price / Book0.673.714.564.15
Net Income-$615.06M-$45.59M$104.42M$214.00M
7 Day Performance-11.37%-8.73%-4.52%-3.51%
1 Month Performance-21.21%-13.05%-6.81%-6.05%
1 Year Performance-69.40%1.62%6.58%3.98%

Vir Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRRK
Scholar Rock
4.4001 of 5 stars
$14.00
+5.0%
$25.17
+79.8%
+92.1%$1.09B$33.19M-7.04150
TARS
Tarsus Pharmaceuticals
3.0768 of 5 stars
$34.90
-0.1%
$48.38
+38.6%
+124.0%$1.19B$17.45M-7.52244Analyst Revision
News Coverage
Positive News
ADAP
Adaptimmune Therapeutics
1.0357 of 5 stars
$1.03
-1.9%
$5.00
+385.4%
-30.7%$1.02B$60.28M-1.87449Gap Up
KYTX
Kyverna Therapeutics
2.5298 of 5 stars
$22.43
-2.0%
$42.75
+90.6%
N/A$986.90M$7.03M0.0096News Coverage
AUTL
Autolus Therapeutics
2.7806 of 5 stars
$4.86
-0.8%
$8.16
+67.9%
+149.7%$1.29B$1.70M-4.08399News Coverage
BCRX
BioCryst Pharmaceuticals
3.5524 of 5 stars
$4.61
-1.3%
$13.29
+188.2%
-40.0%$950.35M$331.41M-3.91536Short Interest ↑
RLAY
Relay Therapeutics
1.8739 of 5 stars
$6.74
-1.3%
$23.69
+251.4%
-52.2%$884.15M$25.55M-2.41323News Coverage
Positive News
FDMT
4D Molecular Therapeutics
2.8826 of 5 stars
$26.75
+1.9%
$44.22
+65.3%
+27.1%$1.37B$20.72M-10.06147News Coverage
IMTX
Immatics
0.0256 of 5 stars
$10.38
-0.2%
N/A+42.4%$878.77M$58.44M-7.98432Short Interest ↑
RGNX
REGENXBIO
4.5594 of 5 stars
$17.50
-2.9%
$38.45
+119.7%
-16.9%$858.20M$90.24M-2.90344Insider Selling
News Coverage

Related Companies and Tools

This page (NASDAQ:VIR) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners